Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Raynaud

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|November 23, 2006
Prostate cancer risk in testosterone-treated menJean-Pierre Raynaud
The Journal of Steroid Biochemistry and Molecular Biology|May 12, 2009
Testosterone deficiency syndrome: treatment and cancer riskJean-Pierre Raynaud
The Journal of Steroid Biochemistry and Molecular Biology|December 13, 2002
Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of PermixonJean Pierre Raynaud, Henri Cousse, Pierre Marie Martin
BJU International|January 9, 2013
Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatmentJean-Pierre Raynaud, Jean Gardette, Jacques Rollet, et al.
European Urology|June 9, 2005
Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or FinasterideAlexandre R Zlotta, Pierre Teillac, Jean Pierre Raynaud, et al.
The Journal of Steroid Biochemistry and Molecular Biology|April 30, 2005
Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week systemJean-Pierre Raynaud, Marc Lévrier, Joaquim Calaf, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 8, 2008
Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal menJean-Pierre Raynaud, Céline Aumonier, Virginie Gualano, et al.
International Journal of Pharmaceutics|June 2, 2009
Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditionsJean-Pierre Raynaud, Marie Augès, Laurent Liorzou, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patientsHenry Botto, Yann Neuzillet, Thierry Lebret, et al.
The Journal of Urology|August 23, 2011
High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosteroneHenry Botto, Yann Neuzillet, Thierry Lebret, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The Journal of Steroid Biochemistry and Molecular Biology|November 23, 2006
Prostate cancer risk in testosterone-treated menJean-Pierre Raynaud
The Journal of Steroid Biochemistry and Molecular Biology|May 12, 2009
Testosterone deficiency syndrome: treatment and cancer riskJean-Pierre Raynaud
The Journal of Steroid Biochemistry and Molecular Biology|December 13, 2002
Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of PermixonJean Pierre Raynaud, Henri Cousse, Pierre Marie Martin
BJU International|January 9, 2013
Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatmentJean-Pierre Raynaud, Jean Gardette, Jacques Rollet, et al.
European Urology|June 9, 2005
Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or FinasterideAlexandre R Zlotta, Pierre Teillac, Jean Pierre Raynaud, et al.
The Journal of Steroid Biochemistry and Molecular Biology|April 30, 2005
Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week systemJean-Pierre Raynaud, Marc Lévrier, Joaquim Calaf, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 8, 2008
Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal menJean-Pierre Raynaud, Céline Aumonier, Virginie Gualano, et al.
International Journal of Pharmaceutics|June 2, 2009
Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditionsJean-Pierre Raynaud, Marie Augès, Laurent Liorzou, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Preoperative low serum testosterone levels are associated with tumor aggressiveness in radical prostatectomy treated cancer patientsHenry Botto, Yann Neuzillet, Thierry Lebret, et al.
The Journal of Urology|August 23, 2011
High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosteroneHenry Botto, Yann Neuzillet, Thierry Lebret, et al.
Pageof 3